2021 CMSC Annual Meeting

Tag: Department of Neurology

Poster-Self-care

Summary of Diet Intervention Studies in Multiple Sclerosis from the National MS Society Nutrition Wellness Subgroup

Background: Increasing evidence suggests that lifestyle factors such as dietary patterns and exercise impact the risk and course of...

Read More

Poster-Imaging

Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study

Background: Cognitive processing speed deficits are common in multiple sclerosis (MS). Despite this, the exact neural mechanism underlying...

Read More

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Alopecia in Multiple Scleoris Patients Treated with Disease Modifying Therapies

Background: There is limited literature about the frequency of alopecia in people with multiple sclerosis (MS) treated with disease...

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcomes By Employment and Education Status for Patients Treated with Peginterferon Beta-1a or Intramuscular Interferon Beta-1a

Background: Although socioeconomic disparities that lead to differences in multiple sclerosis (MS) outcomes have been identified, specific...

Read More

Poster-Disease-modifying Therapy

Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies

Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...

Read More

Poster-Disease-modifying Therapy

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More

Poster-Disease-modifying Therapy

Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS

Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...

Read More